APP Marker Peptide Detection for Alzheimer's Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Alzheimer's disease lack specific biomarkers for detection and effective therapies, relying on general symptoms and non-targeted approaches, which limits diagnostic precision and therapeutic efficacy.
Innovation Solution
Development of specific marker peptides associated with Alzheimer's disease, derived from the Amyloid Precursor Protein (APP), which can be detected using antibodies and used in diagnostic kits and methods to diagnose, treat, and prevent the disease.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current treatments for Alzheimer's disease are used, then general symptom management is achieved, but diagnostic precision and therapeutic efficacy are limited due to lack of specific biomarkers
Solution Approach 1:
The patent segments the Amyloid Precursor Protein (APP) into specific marker peptides (such as Aβ42 and other processed APP fragments) that serve as distinct biomarkers for Alzheimer's disease detection. This segmentation allows for precise identification of disease-specific peptides rather than relying on general symptom assessment, thereby improving diagnostic precision while providing reliable targets for therapeutic intervention
Solution Approach 2:
The patent introduces specific marker peptides and their corresponding antibodies as intermediary elements between the disease pathology and the diagnostic/therapeutic process. These marker peptides serve as mediators that link the underlying neuropathology to detectable biomarkers, enabling both precise diagnosis and targeted therapy development without directly observing the complex disease mechanisms
2Adaptability or versatility
If non-targeted treatment approaches are used, then broad symptom coverage is attempted, but treatment effectiveness is reduced due to lack of specific disease targeting
Solution Approach 1:
The patent applies local quality by identifying specific marker peptides with distinct characteristics (such as Aβ42 and other processed APP fragments) that are locally produced in Alzheimer's disease pathology. This allows treatments to be targeted at specific disease mechanisms rather than applying broad non-specific approaches, improving therapeutic efficacy while maintaining the ability to address different aspects of the disease through different marker peptide targets
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of these marker peptides enables precise detection and potential therapeutic targeting of Alzheimer's disease, offering a more effective diagnostic and treatment approach by identifying specific disease-related peptides and their associated neuropathology.
Implementation Method 1
detecting whether the APP Alzheimer's disease marker peptide is present in the sample by contacting the size fractionated proteins with an antibody that binds a peptide comprising an amino acid sequence of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, or SEQ ID NO:18
Implementation Method 2
size fractionating proteins from the sample; Protein fractionation can be done by size exclusion chromatography
Implementation Method 3
size fractionating proteins from the sample; Protein fractionation can be done by size exclusion chromatography, gel electrophoresis
Data Source
AI summary
Certain embodiments are directed to marker peptides or marker peptide antibodies can be used in producing diagnostic kits or used in diagnostic methods for Alzheimer's disease. The antibodies and/or marker peptides can be used in immunohistochemical and biochemical methods for qualitative and quantitative analysis of marker peptide levels and/or localization in brain samples and CSF samples.